Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of siRNA targeting FGF5 in the treatment of hair loss

A hair loss and composition technology, applied in the field of screening these substances, can solve the problem of low transfection efficiency of siRNA

Active Publication Date: 2022-01-11
WENZHOU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this method of administration can cause excruciating pain, and the transfection efficiency of siRNA is not high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of siRNA targeting FGF5 in the treatment of hair loss
  • Application of siRNA targeting FGF5 in the treatment of hair loss
  • Application of siRNA targeting FGF5 in the treatment of hair loss

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Design, synthesis and cholesterol modification of embodiment 1siRNA

[0040] According to the mRNA sequence of mouse FGF5 in Gene Bank, siRNA design was performed using online open software. Because different design software uses different algorithms, the design principles also have their own emphasis. As an example, to improve the accuracy of siRNA design, we compared the characteristics of each software, and finally selected 3 kinds of software with strong technical support and continuous updating. The software SiDirect, Oligowalk and SiRNA Design are used for siRNA design, and siRNAs with high repetition rates are selected from the output sequences as candidate siRNAs for further cell biology experiment screening to confirm their gene interference activity.

[0041] The synthesis of candidate siRNAs and the covalent modification of cholesterol at the 5' end were entrusted to Shanghai Gemma Pharmaceutical Technology Co., Ltd.

Embodiment 2

[0042] Example 2 Screening of siRNA and evaluation of target gene interference effect of different siRNA delivery methods

[0043] Since the cell line expressing FGF5 is currently unavailable, in this study, the eukaryotic expression plasmid of mouse FGF5 was constructed, transfected into NIH / 3T3 cells, and the NIH / 3T3 cells overexpressing mouse FGF5 were used to screen candidate siRNAs. The eukaryotic expression plasmid of mouse FGF5 can be prepared according to conventional methods in the art.

[0044] (1) NIH / 3T3 cells that have been transfected with the expression plasmid of FGF5 were treated with 1×10 5 The density of cells / well was inoculated into 6-well plate, cultured in 2ml of complete medium containing serum and double antibody, when the cell density reached 80%, replaced with 2ml of serum-free cell culture medium;

[0045] (2) Take 200 pmol of siRNA and dilute it in 100 μl of serum-free and double-antibody-free medium, add 4 μl of lipofectamine 2000 to another 10...

Embodiment 3

[0048] Example 3 Screening of siRNA transfection delivery system

[0049] 1. Cholesterol-modified siRNA transfection

[0050] (1) NIH / 3T3 cells that had been transfected with FGF5 expression plasmid were treated with 1×10 5 The density of cells / well was inoculated into 6-well plates, cultured in 2ml of cell culture medium containing serum and double antibody, when the cell density reached 80%, replace with fresh complete medium;

[0051] (2) Dilute 200 pmol of cholesterol-modified siRNA (entrusted to Gemma Gene Co., Ltd. to modify according to conventional technical means in the field) in 200 μl of serum-free and double-antibody-free medium, mix gently, let stand for 5 minutes, and add to 6 wells plate, placed in 5% CO 2 , cultured in a cell incubator at 37°C for 24 hours;

[0052] (3) The cells were collected, and the mRNA level of the FGF5 gene in the cells was detected by qPCR.

[0053] 2. Penetrating peptide-mediated siRNA transfection

[0054] (1) NIH / 3T3 cells tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a siRNA combination for treating hair loss, the siRNA combination has a significant inhibitory effect on FGF5 in skin tissue, and the present invention also provides a delivery system for delivering the siRNA combination.

Description

technical field [0001] The present invention relates to a hair growth promoting agent, a hair regeneration promoting agent or a hair loss treatment agent comprising a substance that inhibits the growth of hair follicles, and a method for screening these substances. Background technique [0002] With the accelerated pace of life and increasing work pressure, more and more people are suffering from hair loss. Taking the most common androgenetic alopecia (referred to as androgenetic alopecia) as an example, the incidence rate of men over 50 years old is as high as About 50%, and for every 10 years of age increase, the incidence of male baldness will increase by 10%. The upward movement of the hairline and thinning hair will bring psychological burden and stress to people, and affect the quality of life of baldness patients. Therefore, there is a high demand for anti-hair loss and hair growth treatments. At present, there are mainly finasteride and minoxidil in the clinical tre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7105A61K48/00A61P17/14
CPCA61K31/7105A61P17/14
Inventor 高爽许诺李校堃胡振林陈毓赵文刚
Owner WENZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com